Zyme Base

ZymeBase is a Canadian biotechnology company that specializes in the development of enzymatic synthesis technologies for high-value functional ingredients. The company's core expertise lies in producing human milk oligosaccharides (HMOs), which are critical for infant gut health and immune system development. By utilizing a proprietary biocatalysis platform, ZymeBase offers a more efficient and scalable production method compared to traditional fermentation or chemical synthesis. In January 2024, the company was acquired by Kyowa Hakko Bio, a subsidiary of Kirin Holdings, to strengthen its position in the global health science and nutrition markets.